STACK_RATINGSby NERD_PROTOCOLS
< LEADERBOARD/s/artichokeBotanicals

Artichoke

Also sold as: Artichoke leaf extract · Cynara scolymus · Cynarin

Leaf extracts studied for functional dyspepsia and modest changes in blood lipids and fatty-liver markers. Food artichokes and tea are different exposures from standardized extracts.

Longevity

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

LongevityNo established evidence
  • Longevity: Human lifespan benefit is unestablished; lipid and liver-enzyme changes are surrogate outcomes, not longevity trials.

REALITY CHECK // Artichoke is not a liver detox or an established SIBO cure. The strongest digestive evidence concerns functional dyspepsia; lipid and liver studies mainly measure surrogate markers. Increased bile flow makes obstruction a contraindication and gallstones a reason for medical review.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Try a common label:
The label number is the…

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE
320–1,800 mg/day extract
Aggregate dossier trial range, not a universal dose or equivalence rule; marker standards vary.
02 // TIMING_&_MATRIX
Product-specific timing
No convincing comparison of before-meal versus bedtime dosing for the migrating motor complex is supplied.
03 // EVALUATION_WINDOW
6–12 weeks
Dyspepsia was studied over six weeks; metabolic studies commonly lasted 5–12 weeks or longer.
04 // SAFETY_&_QUALITY_GATE
Biliary and allergy screen
Obstruction is contraindicated; gallstones and Asteraceae allergy require particular care.

UPPER LIMIT // No formal EFSA or NIH tolerable upper intake level is established in the dossier. The 320–1,800 mg/day trial range is not a safety ceiling; long-term and pregnancy data are insufficient.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

Standardized leaf extract has a six-week placebo-controlled dyspepsia trial and heterogeneous lipid and fatty-liver studies. IBS reports are uncontrolled. Biliary obstruction is a contraindication even when the intended use is digestion or liver support.

Mechanism

Caffeoylquinic acids and flavonoids are absorbed and metabolized in humans. Increased bile secretion is a measured pharmacodynamic effect; cynarin is a marker within a complex extract rather than the sole active ingredient.

Typical studied dose

The dossier reports approximately 320–1,800 mg/day of leaf extract across trials, typically 5–12 weeks; the dyspepsia trial lasted six weeks. Standards differ, so this aggregate range cannot establish equivalent potency between products. No validated SIBO prokinetic dose is supplied.

Upper limit

No formal EFSA or NIH tolerable upper intake level is established in the dossier. The 320–1,800 mg/day trial range is not a safety ceiling; long-term and pregnancy data are insufficient.

POPULAR_STACKScombos with n ≥ 5

Popular stacks with Artichoke

Not enough stack data yet. A combination with Artichoke appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on labelActive contentStudied range / dayAbsorption & GI toleranceVerdict
Leaf extract labelled 5% caffeoylquinic acids
Best for: Matching a standardized leaf-extract specification.
 Extract weight · ~5% marker 320–1800 mg Human pharmacokinetic data support absorption of constituents, not a universal bioavailability percentage.
Usually tolerated; gas or bloating can occur.		 Studied standard [FORM // REFERENCE]
The 5% is a label-marker example within the dossier range of 2.5–5%; compare full extract mass, not just cynarin milligrams.
Artichoke leaf juice
Best for: Evaluating a juice label separately from an extract.
 Unstandardized: active content unknown no comparable trial range A hypertension trial studied juice; concentration varies.
Generally tolerated in the dossier.		 Caution [FORM // CHECK_LABEL]
No reproducible milligram trial interval is supplied; zero denotes unavailable, not an ineffective dose.
Culinary artichoke or leaf tea
Best for: Food use.
 Unstandardized: active content unknown no comparable trial range Not equivalent to the concentrated leaf preparations used in trials.
Food tolerance differs from extract tolerance.		 Caution [FORM // CHECK_LABEL]
Marker content is unknown; no extract conversion or therapeutic equivalence is justified.

Common label traps

  • TRAP_01 // Liver detox
    Lower ALT/AST or steatosis markers do not establish toxin removal, reversal of fibrosis or prevention of liver events.
  • TRAP_02 // 19% cholesterol and 16% LDL reduction from artichoke alone
    These headline percentages come from an artichoke-plus-Berberis combination and cannot be assigned to artichoke.
  • TRAP_03 // Artichoke plus ginger cures SIBO
    Popularity and uncontrolled experience do not establish eradication or superiority to prescribed prokinetics.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

  • LDL / TOTAL CHOLESTEROL Moderate · benefit
    Systematic reviews suggest modest reductions in adults with high cholesterol over roughly 5–12 weeks. Extract heterogeneity is substantial; this does not replace indicated lipid therapy.
    PMID 28609140 PMID 23543518
  • COMBINATION LIPID PRODUCTS Limited · benefit
    Combination RCTs show lipid improvements, including the often quoted 19% total-cholesterol and 16% LDL reductions in one combination; the artichoke contribution cannot be isolated.
    PMID 30528419 PMID 37732047
  • FATTY-LIVER MARKERS Moderate · benefit
    Small RCTs and a meta-analysis suggest lower liver enzymes and improved steatosis markers after 8–12 weeks; no demonstrated reduction in fibrosis progression or liver events.
    PMID 35763310 PMID 29520889 PMID 34533249
  • FUNCTIONAL DYSPEPSIA Moderate · benefit
    A six-week multicenter blinded RCT improved symptoms and quality of life versus placebo.
    PMID 14653829
  • IBS Anecdotal · benefit
    Post-marketing surveillance and a subgroup analysis report symptom improvement without adequate placebo control; causality remains unestablished.
    PMID 11180525 PMID 15353023
  • GLYCEMIC MARKERS Limited · benefit
    Heterogeneous RCT meta-analyses suggest small changes, most relevant as a caution alongside glucose-lowering drugs.
    PMID 32951745 PMID 41270328
  • BLOOD PRESSURE Limited · benefit
    Small heterogeneous trials suggest modest reductions; not an established substitute for antihypertensive treatment.
    PMID 33465383 PMID 35949557
  • BILE SECRETION Limited · benefit
    Human pharmacodynamic work found increased bile secretion; a separate preparation study was preclinical. This is a mechanism, not proof of improved clinical liver outcomes.
    PMID 23195882 PMID 12738088

Reader questions

What dose works for digestion or SIBO?

The extract range in the dossier is 320–1,800 mg/day across different trials; the dyspepsia study lasted six weeks. A validated SIBO prokinetic regimen and extract-equivalence rule are not supplied.

Before meals or at bedtime?

The source does not establish superiority of either schedule or prove a migrating-motor-complex effect.

Can this replace a prokinetic or a statin?

No comparative evidence here establishes equivalence to prescribed prokinetics; lipid benefits are modest and do not replace risk-based treatment.

Why might it worsen symptoms?

Gas and bloating occur. Severe abdominal pain, especially with gallstones, needs assessment rather than escalating a bile-stimulating extract.

Stack interactions

  • Caution Diabetes medicines [CAUTION // REVIEW_CONTEXT]
    Possible additive glucose lowering; the meta-analysis concerns glycemic outcomes, not a dedicated drug-interaction trial. Medication changes require the treating clinician.
    PMID 32951745
  • Caution Berberine or red yeast rice [CAUTION // REVIEW_CONTEXT]
    Combination trials report lipid changes, but other active ingredients confound attribution. These products do not establish artichoke monotherapy effect size.
    PMID 30528419 PMID 37732047
  • Caution Anticoagulants [CAUTION // REVIEW_CONTEXT]
    Clinically important interaction is unconfirmed in this dossier; this is a precaution rather than a documented anticoagulant effect.

Red flags: interactions and who should avoid it

Interactions

Glucose-lowering effects may add to diabetes medicines. Anticoagulant interaction is theoretical and unverified. Lipid combinations with berberine or red yeast rice cannot isolate the artichoke contribution; ginger combinations lack strong SIBO evidence.

Avoid or ask a doctor first if

Avoid with bile-duct obstruction; gallstones warrant medical review because increased bile secretion can provoke colic. Avoid with Asteraceae allergy; pregnancy, lactation and pediatric safety are insufficiently studied. Gas and bloating can occur; severe upper abdominal pain or allergic symptoms require stopping and assessment.

Sources (PubMed, 18)

  1. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis.
    PMID 28609140 · 2018 · systematic review and meta-analysis
    Review of modest lipid-lowering effects of artichoke extracts.
  2. Artichoke leaf extract for treating hypercholesterolaemia.
    PMID 23543518 · 2013 · systematic review and meta-analysis
    Earlier review of artichoke leaf extract for high cholesterol.
  3. Short-Term Effects of Dry Extracts of Artichokeand Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease.
    PMID 30528419 · 2019 · randomized controlled trial
    Combination extract trial; the lipid percentages cannot be assigned to artichoke alone.
  4. Three arms, double-blind, non-inferiority, randomized clinical study testing the lipid-lowering effect of a novel dietary supplement containing red yeast rice and artichoke extracts compared to Armolipid Plus&#xae; and placebo.
    PMID 37732047 · 2023 · randomized controlled trial
    Red-yeast-rice and artichoke combination study with active comparator.
  5. Therapeutic Potential of Artichoke in the Treatment of Fatty Liver: A Systematic Review and Meta-Analysis.
    PMID 35763310 · 2022 · systematic review and meta-analysis
    Meta-analysis of fatty-liver outcomes, mainly surrogate markers.
  6. Efficacy of artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial.
    PMID 29520889 · 2018 · randomized controlled trial
    Pilot placebo-controlled fatty-liver trial.
  7. The effects of co-administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial.
    PMID 34533249 · 2021 · randomized controlled trial
    Fatty-liver adjunct trial with metformin and vitamin E.
  8. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial.
    PMID 14653829 · 2003 · randomized controlled trial
    Six-week placebo-controlled functional-dyspepsia trial.
  9. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study.
    PMID 11180525 · 2001 · observational study
    Uncontrolled post-marketing IBS symptom observations.
  10. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis.
    PMID 15353023 · 2004 · observational subset analysis
    IBS subgroup analysis, not treated here as a randomized IBS monotherapy trial.
  11. Effects of Cynara scolymus L. on glycemic indices:A systematic review and meta-analysis of randomized clinical trials.
    PMID 32951745 · 2020 · systematic review and meta-analysis
    Meta-analysis of glycemic indices supporting a glucose-monitoring precaution.
  12. Artichoke and cardiometabolic health: A systematic and meta-analytic synthesis of current evidence.
    PMID 41270328 · 2025 · systematic review and meta-analysis
    Cardiometabolic synthesis with small heterogeneous effects.
  13. Effects of artichoke on blood pressure: A systematic review and meta-analysis.
    PMID 33465383 · 2021 · systematic review and meta-analysis
    Meta-analysis of blood-pressure outcomes.
  14. Anti-hypertensive Effects of Artichoke Supplementation in Adults: A Systematic Review and Dose-response Meta-analysis of Randomized Controlled Trials.
    PMID 35949557 · 2022 · systematic review and meta-analysis
    Dose-response review of blood-pressure trials.
  15. Artichoke leaf juice contains antihypertensive effect in patients with mild hypertension.
    PMID 22435514 · 2009 · randomized controlled trial
    Leaf-juice hypertension study; not interchangeable with capsules.
  16. Increase in choleresis by means of artichoke extract.
    PMID 23195882 · 1994 · randomized controlled trial
    Human bile-secretion pharmacodynamic study.
  17. Efficacy of different Cynara scolymus preparations on liver complaints.
    PMID 12738088 · 2003 · animal study
    Animal evidence comparing preparations.
  18. Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans.
    PMID 15693705 · 2005 · human pharmacokinetic study
    Human pharmacokinetics of caffeoylquinic acids and flavonoids.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this